DGIdb - CILOSTAZOL Drug Record

CILOSTAZOL chembl:CHEMBL799 Approved

Alternate Names:

PLETAL
OPC-21
OPC-13013
CILOSTAZOL
6-(4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY)-3,4-DIHYDRO-2(1H)-QUINOLINONE
3,4-DIHYDRO-6-(4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY)-2(1H)-QUINOLINONE
PLETAL®
6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)-BUTOXY]-3,4-DIHYDRO-1H-QUINOLIN-2-ONE
CILOSTAZOLE
6-(4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY)-3,4-DIHYDROCARBOSTYRIL
CILOSTAZOLUM
chemidplus:73963-72-1
pubchem.compound:2754
rxcui:21107
drugbank:01166
chembl:CHEMBL799

Drug Info:

FDA Approval	1999
Drug Class	small molecule
Drug Indications	Platelet Aggregation Inhibitors
Drug Class	platelet aggregation inhibitors
Year of Approval	1999

(5 More Sources)

Publications:

Schrör, 2002, The pharmacology of cilostazol., Diabetes Obes Metab
Mokry et al., 2008, Influence of selective inhibitors of phosphodiesterase 3 and 4 on cough and airway reactivity., J. Physiol. Pharmacol.
Hong et al., 2006, Cilostazol: therapeutic potential against focal cerebral ischemic damage., Curr. Pharm. Des.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Parkkonen et al., 2008, Phosphodiesterase 4 inhibitors delay human eosinophil and neutrophil apoptosis in the absence and presence of salbutamol., Pulm Pharmacol Ther
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Hayakawa et al., 2000, Effects of beraprost and cilostazol and renal function on serum thrombomodulin levels in diabetic patients., Arzneimittelforschung
Wang et al., 2005, Inhibition of eosinophil survival by a selective inhibitor of phosphodiesterase 4 via the induction of apoptosis., Biol. Pharm. Bull.
Lee et al., 2001, Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication., Clin. Sci.

CILOSTAZOL PDE3A

Interaction Score: 2.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Phosphodiesterase 3A inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

PMIDs:
12180353 19218671 16472148 11752352 18282775

Sources:
TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology TTD
CILOSTAZOL THBD

Interaction Score: 1.96

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10918946

Sources:
NCI
CILOSTAZOL PDE3B

Interaction Score: 0.45

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
None found

Sources:
GuideToPharmacology
CILOSTAZOL VEGFA

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11524048

Sources:
NCI
CILOSTAZOL CSF2

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15744080

Sources:
NCI
CILOSTAZOL TSHR

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CILOSTAZOL CYP3A5

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CILOSTAZOL CYP2C9

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CILOSTAZOL CYP2C19

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CILOSTAZOL CYP1A2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CILOSTAZOL CYP2D6

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CILOSTAZOL ALDH1A1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CILOSTAZOL CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: CILOSTAZOL
- Version: 01-August-2011
Alternate Names:

CILOSTAZOL Primary Drug Name

Drug Info:

Year of Approval 1999

Drug Class platelet aggregation inhibitors

Publications:
TdgClinicalTrial: CILOSTAZOL
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Platelet Aggregation Inhibitors

Drug Class small molecule

FDA Approval 1999

Publications:

NCI: CILOSTAZOL

Version: 14-September-2017

Alternate Names:

C1051 NCI drug code

Drug Info:

Publications:

Lee et al., 2001, Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication., Clin. Sci.

Wang et al., 2005, Inhibition of eosinophil survival by a selective inhibitor of phosphodiesterase 4 via the induction of apoptosis., Biol. Pharm. Bull.

Hayakawa et al., 2000, Effects of beraprost and cilostazol and renal function on serum thrombomodulin levels in diabetic patients., Arzneimittelforschung

DTC: CILOSTAZOL
- Version: 02-September-2020
Alternate Names:

CHEMBL799 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
TTD: Cilostazol
- Version: 2020.06.01
Alternate Names:

D03VPC TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178103723
- Version: 29-September-2020
Alternate Names:

CILOSTAZOL GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL799
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL799
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
PharmGKB: cilostazol
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Phosphodiesterase 3A inhibitor
Direct Interaction	yes
Specific Action of the Ligand	Inhibition

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	True

CILOSTAZOL Drug Record

CILOSTAZOL chembl:CHEMBL799 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Phosphodiesterase 3A inhibitor Direct Interaction yes Specific Action of the Ligand Inhibition

PMIDs: 12180353 19218671 16472148 11752352 18282775

Sources: TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10918946

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? True

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11524048

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15744080

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

TEND: CILOSTAZOL

Alternate Names: CILOSTAZOL Primary Drug Name

Drug Info: Year of Approval 1999 Drug Class platelet aggregation inhibitors

Publications:

TdgClinicalTrial: CILOSTAZOL

Alternate Names:

Drug Info: Drug Indications Platelet Aggregation Inhibitors Drug Class small molecule FDA Approval 1999

Publications:

NCI: CILOSTAZOL

Alternate Names: C1051 NCI drug code

Drug Info:

DTC: CILOSTAZOL

Alternate Names: CHEMBL799 ChEMBL Drug ID

Drug Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

TTD: Cilostazol

Alternate Names: D03VPC TTD Drug ID

Drug Info:

Publications:

GuideToPharmacology: 178103723

Alternate Names: CILOSTAZOL GuideToPharmacology Ligand Name

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Phosphodiesterase 3A inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

PMIDs:
12180353 19218671 16472148 11752352 18282775

Sources:
TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology TTD

Interaction Types & Directionality:

n/a

PMIDs:
10918946

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
11524048

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15744080

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

CILOSTAZOL Primary Drug Name

Drug Info:

Year of Approval 1999

Drug Class platelet aggregation inhibitors

Drug Info:

Drug Indications Platelet Aggregation Inhibitors

Drug Class small molecule

FDA Approval 1999

Alternate Names:

C1051 NCI drug code

Alternate Names:

CHEMBL799 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Alternate Names:

D03VPC TTD Drug ID

Alternate Names:

CILOSTAZOL GuideToPharmacology Ligand Name